Metabolic phenotyping for monitoring ovarian cancer patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ke, Chaofu ^a   Li, Ang ^a   Hou, Yan ^a   Sun, Meng ^a   Yang, Kai ^a   Cheng, Jinlong ^a   Wang, Jingtao ^a   Ge, Tingting ^a   Zhang, Fan ^a   Li, Qiang ^a   Li, Junnan ^a   Wu, Ying ^a   Lou, Ge ^a   Li, Kang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; METABOLOMICS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PHENOTYPE;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; HUMANS; METABOLOMICS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE;

EID: 84961786453     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23334     Document Type: Article

References (39)

1. Rauh-Hain, J. A., Krivak, T. C., Del Carmen, M. G., Olawaiye, A. B. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 4, 15-21 (2011).
2. Hennessy, B. T., Coleman, R. L., Markman, M. Ovarian cancer. Lancet 374, 1371-1382 (2009).
3. Kim, A., Ueda, Y., Naka, T., Enomoto, T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 31, 14 (2012).
4. Chien, J., Kuang, R., Landen, C., Shridhar, V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Frontiers in oncology 3, 251 (2013).
5. Benjamin, D. I., Cravatt, B. F., Nomura, D. K. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab 16, 565-577 (2012).
6. Nicholson, J. K., Lindon, J. C. Systems biology: Metabonomics. Nature 455, 1054-1056 (2008).
7. Chen, J. et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res 10, 2625-2632 (2011).
8. Ben Sellem, D. et al. Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy. J Oncol 2011, 174019 (2011).
9. Fong, M. Y., McDunn, J., Kakar, S. S. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PloS one 6, e19963 (2011).
10. Zhang, T. et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 413, 861-868 (2012).
11. Fan, L. et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta oncologica 51, 473-479 (2012).
12. Zhang, T. et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res 12, 505-512 (2013).
13. Ke, C. et al. Large-scale profiling of metabolic dysregulation in ovarian cancer. International journal of cancer. Journal international du cancer 136, 516-526 (2015).
14. Zhang, H. et al. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling. Mol Biosyst 11, 516-521 (2015).
15. Vorkas, P. A. et al. Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease. Anal Chem 87, 4184-4193 (2015).
16. Sun, M. et al. Identification of biomarkers for unstable angina by plasma metabolomic profiling. Mol Biosyst 9, 3059-3067 (2013).
17. Yu, Z. et al. Human serum metabolic profiles are age dependent. Aging Cell 11, 960-967 (2012).
18. Auro, K. et al. A metabolic view on menopause and ageing. Nat Commun 5, 4708 (2014).
19. Ke, C. et al. Plasma Metabolic Profiles in Women are Menopause Dependent. PloS one 10, e0141743 (2015).
20. Tania, M., Khan, M. A., Song, Y. Association of lipid metabolism with ovarian cancer. Current oncology 17, 6-11 (2010).
21. Santos, C. R., Schulze, A. Lipid metabolism in cancer. FEBS J 279, 2610-2623 (2012).
22. Lenaz, G., Genova, M. L. Mobility and function of coenzyme Q (ubiquinone) in the mitochondrial respiratory chain. Biochim Biophys Acta 1787, 563-573 (2009).
23. Saugstad, O. D. Hypoxanthine as an indicator of hypoxia: its role in health and disease through free radical production. Pediatr Res 23, 143-150 (1988).
24. Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363, 943-953 (2010).
25. Qiu, Y. et al. Urinary metabonomic study on colorectal cancer. J Proteome Res 9, 1627-1634 (2010).
26. Hwang, I. K. et al. Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 87, 2126-2137 (2009).
27. Muteliefu, G., Enomoto, A., Jiang, P., Takahashi, M., Niwa, T. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 24, 2051-2058 (2009).
28. Glantzounis, G. K., Tsimoyiannis, E. C., Kappas, A. M., Galaris, D. A. Uric acid and oxidative stress. Curr Pharm Des 11, 4145-4151 (2005).
29. Cerantola, Y. et al. Perioperative nutrition in abdominal surgery: recommendations and reality. Gastroenterol Res Pract 2011, 739347 (2011).
30. Borst, P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol 2, 120066 (2012).
31. Poisson, L. M. et al. A metabolomic approach to identifying platinum resistance in ovarian cancer. Journal of ovarian research 8, 13 (2015).
32. Allott, E. H. et al. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23, 2349-2356 (2014).
33. Platten, M., Wick, W., Van den Eynde, B. J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer research 72, 5435-5440 (2012).
34. Godin-Ethier, J., Hanafi, L. A., Piccirillo, C. A., Lapointe, R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clinical cancer research: an official journal of the American Association for Cancer Research 17, 6985-6991 (2011).
35. Suresh, K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci 4, 8-11 (2011).
36. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R., Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78, 779-787 (2006).
37. Kuhl, C., Tautenhahn, R., Bottcher, C., Larson, T. R., Neumann, S. CAMERA: an integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets. Anal Chem 84, 283-289 (2012).
38. Trygg, J., Holmes, E., Lundstedt, T. Chemometrics in metabonomics. J Proteome Res 6, 469-479 (2007).
39. Westerhuis, J. A. et al. Assessment of PLSDA cross validation. Metabolomics 4, 81-89 (2008).